Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
In this paper the preliminary results from an ongoing investigation on the effect of the MAO-A inhibitor moclobemide on clinicolaboratory variables (antidepressant effect, platelet MAO activity, urinary MHPG and 5-HIAA excretion, plasma prolactin and growth hormone levels and TSH response to TRH) are reported. From the total of 18 patients, 10 (2 males and 8 females) responded favourably (reduction in the HDRS 50% or more) to the treatment. Urine MHPG excretion significantly (p less than 0.001) decreased during treatment, while 5-HIAA secretion showed a less pronounced decrease (p less than 0.05). Plasma PRL and GH remained unchanged, while the TSH-response to TRH increased significantly (p less than 0.025) after 4-week treatment. A significant correlation was found between MHPG pretreatment values and treatment outcome.
D000328:Adult; D001549:Benzamides / Q000627:therapeutic use*; D001792:Blood Platelets / Q000201:enzymology; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine; D008875:Middle Aged; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000097:blood; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D013972:Thyrotropin / Q000097:blood
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D011388:Prolactin; D013972:Thyrotropin; D013006:Growth Hormone; D008995:Monoamine Oxidase; D020912:Moclobemide